Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
批准号:
9285707
负责人:
Tracy Minan Frech
金额:
$17.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2021-06-30
关键词:
AdoptedAntioxidantsAutoimmune DiseasesBiological MarkersBiopsyBlood VesselsCaliberCicatrixClinic VisitsClinicalConsentDataDevelopmentDiseaseDouble-Blind MethodEarly DiagnosisEnzymesEventFDA approvedFibrosisFunctional disorderImpairmentInterventionLinkLongitudinal StudiesMeasuresMediatingMolecularMonitorNADPH OxidaseOralOutcomeOxidantsOxidative StressPathogenicityPatientsPeripheralPharmaceutical PreparationsPharmacologyPredictive ValueProcessRandomizedReportingRiskScientistSclerodermaSkinSolidSystemic SclerodermaTechniquesTestingTherapeuticUlcerVascular Diseasesantioxidant enzymearteriolebasebrachial arterycollaborative approachdesigndigitalexperienceimprovedimproved outcomeinsightnovelpublic health relevancereactive hyperemiaresponseskillstetrahydrobiopterinvascular endothelial dysfunction
中文摘要
描述(申请人提供):系统性硬化症(SSC;硬皮病)是一种复杂的自身免疫性疾病,以血管病变(血管病变)和疤痕形成(纤维化)为特征。SSc是一种血管变化先于纤维化的疾病。最重要的是,早期诊断可能会改善SSc患者的预后。我们使用血流介导的扩张(FMD)的先导数据表明,与健康对照组相比,SSC患者的肱动脉内径显著缩小,外周血管反应性和内皮功能减弱。与无指端溃疡(DU)的患者相比,有指端溃疡(DU)的SSC患者的内皮功能受损更严重。FMD检测对鉴别有DU风险的SSc患者有潜在的临床应用价值,有望成为SSc血管病变纵向研究的一个有前景的生物标志物。口蹄疫可用于描述SSc治疗的致病过程或药理反应。因此,该项目将建立一个坚实的初始技能和经验基础,不仅将Frech博士培养成一名独立的临床科学家,而且将通过协作方法仔细描述SSC患者的血管病变特征,并在可能最有可能影响结果的情况下提供针对内皮的临床干预。在第一个具体目标中,血管病变对SSC患者的影响将通过患者相关和报告的结果(PRO)进行评估,FMD测试将在基线和临床访问期间每隔6个月进行一次。FMD对SSC并发症(终末期血管病变)发展的预测价值将被确定。对于同意皮肤活检的患者,将评估全身、细胞和分子事件,如循环和皮肤小动脉ROS衍生的自由基种类、循环和皮肤小动脉氧化剂损伤的标志物、皮肤小动脉氧化酶NADPH氧化酶和循环抗氧化剂的表达以及皮肤小动脉抗氧化酶的表达。在第二个具体目标中,将采用随机双盲设计,在没有或存在口服BH4治疗5天的情况下,通过测量有或没有并发症(即终末期血管病)的SSc患者的FMD和反应性充血来评估血管功能。在同意皮肤活检的患者中,氧化应激标志物的相关性分析将采用随机交叉双盲设计,在没有或存在口服BH4治疗的情况下,对有和没有并发症的SSC患者进行评估。总之,建议的研究将采用一种综合的方法来更好地定义SSc血管病变的病理生理学。我们将验证一种新的、非侵入性的技术来评估SSc的血管病变。此外,我们将检查FDA批准的药物BH4是否有效改善SSc患者的血管功能障碍。最后,为了提供进一步的机制洞察,我们将探索氧化应激与SSC中血管内皮功能障碍之间的联系。如果成功,这些目标有可能改善SSC的临床结果。
英文摘要
DESCRIPTION (provided by applicant): Systemic sclerosis (SSc; scleroderma) is a complicated autoimmune disease characterized by blood vessel change (vasculopathy) and scarring (fibrosis). SSc is a disease in which the blood vessel changes precede fibrosis. Most importantly, early diagnosis may result in improved outcomes for SSc patients. Our pilot data using flow-mediated dilation (FMD), a noninvasive, objectively measured parameter, suggests that compared to healthy controls, SSc patients had significantly smaller brachial artery diameter, and blunted peripheral vascular reactivity and endothelial function. SSc patients with digital ulcers (DU) have even greater impairments in endothelial function compared to those without DU. FMD testing potentially has clinical utility to identify SSc patients at risk for DU an may be a promising biomarker of SSc-vasculopathy longitudinal studies. FMD may be used to describe pathogenic processes or pharmacologic response to SSc therapeutics. As such, this project will establish a solid initial base of skills and experiences that will not only develop Dr Frech as an independent clinician scientist, but will result in a careful characterization of the vasculopathy in patients with SSc through a collaborative approach and provide an endothelial targeted clinical intervention when it may have the largest potential to impact outcomes. In the first specific aim, the impact of vasculopathy on SSc patients will be assessed through patient-related and reported outcomes (PRO) and FMD testing will be performed at baseline and at 6 month intervals during clinic visits. The predictive value of FMD for the development of SSc complications (end-stage vasculopathies) will be determined. In patients who consent to skin biopsy, systemic, cellular and molecular events such as circulating and skin arteriole ROS-derived radical species, circulating and skin arteriolar markers of oxidant damage, skin arteriole expression of the oxidant enzyme NADPH oxidase and circulating antioxidants and skin arteriole expression of antioxidant enzymes will be assessed. In the second specific aim, vascular function will be assessed by measuring FMD and reactive hyperemia in patients with SSc with and without complications (i.e. end-stage vasculopathy) in the absence or presence of oral BH4 treatment for 5 days using a randomized cross-over double-blind design. In patients who consent to skin biopsy correlation analysis of oxidative stress markers will be assessed in patients with SSc with and without complications in the absence or presence of oral BH4 treatment using a randomized cross-over, double-blind design. In summary, the proposed studies will adopt an integrative approach to better define the pathophysiology of vasculopathy in SSc. We will validate a novel, non-invasive technique to evaluate vasculopathy in SSc. Additionally, we will examine if BH4, a FDA-approved drug, is effective in ameliorating vascular dysfunction in patients with SSc. Finally, to provide further mechanistic insight, we will explore the link between oxidative stress and the vascular endothelial dysfunction in SSc. If successful, these aims have the potential to improve clinical outcomes in SSc.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Systemic sclerosis (SSc) vasculopathy: Improved clinical monitoring and treatment
-
批准号:10613002
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Tracy Minan Frech
-
依托单位:
Systemic sclerosis (SSc) vasculopathy: Improved clinical monitoring and treatment
-
批准号:10252115
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Tracy Minan Frech
-
依托单位:
Systemic sclerosis (SSc) vasculopathy: Improved clinical monitoring and treatment
-
批准号:10426267
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Tracy Minan Frech
-
依托单位:
海外基金